

Adherence, persistence, and medication discontinuation
attention-deficit/hyperactivity disorder – a

Neuropsychiatric Disease and Treatment

10, 1543

DOI: [10.2147/ndt.s65721](https://doi.org/10.2147/ndt.s65721)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emotional Dysregulation in a Child with Attention-Deficit/Hyperactivity Disorder and Anxiety: Psychopharmacological Strategies. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 590-593.	0.7	2
2	Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 936-942.	1.9	6
3	Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making. <i>Arthritis Research and Therapy</i> , 2015, 17, 367.	1.6	13
4	Adderall XR and peripheral arterial vasculopathy: A case report and a review of the literature. <i>Reviews in Vascular Medicine</i> , 2015, 3, 1-4.	0.4	2
5	Severe Salt-Losing 3 β -Hydroxysteroid Dehydrogenase Deficiency: Treatment and Outcomes of Homozygotes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1105-E1115.	1.8	26
6	Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database. <i>Journal of Korean Medical Science</i> , 2016, 31, 1284.	1.1	6
7	Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan. <i>PLoS ONE</i> , 2016, 11, e0161061.	1.1	32
8	Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine. <i>Patient Preference and Adherence</i> , 2016, 10, 391.	0.8	2
9	A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study. <i>Journal of Neural Transmission</i> , 2016, 123, 859-865.	1.4	12
10	Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 45-53.	0.9	7
11	Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort Study. <i>Clinical Therapeutics</i> , 2016, 38, 1789-1802.	1.1	4
12	Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 970-978.	1.9	1
13	Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network. <i>BMC Psychiatry</i> , 2016, 16, 301.	1.1	45
14	Stimulant Medications and Cognition, Behavior and Quality of Life in Children and Youth with HIV. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e12-e18.	1.1	4
15	A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. <i>Journal of Psychopharmacology</i> , 2016, 30, 444-458.	2.0	24
16	A comparative consecutive case series of 20 children with a diagnosis of ADHD receiving homeopathic treatment, compared with 10 children receiving usual care. <i>Homeopathy</i> , 2016, 105, 194-201.	0.5	5
17	Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 354-361.	0.7	8
18	Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine. <i>Clinical Therapeutics</i> , 2016, 38, 595-602.	1.1	10

#	ARTICLE	IF	CITATIONS
19	Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. <i>Clinical Drug Investigation</i> , 2016, 36, 1-25.	1.1	44
20	Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan. <i>Journal of Affective Disorders</i> , 2016, 189, 110-117.	2.0	37
21	Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 10-18.	0.7	6
22	New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability. <i>CNS Drugs</i> , 2017, 31, 149-160.	2.7	25
23	Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 690-699.	0.7	21
24	Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 87-99.	1.0	27
25	Influence of Written Informed Consent for Methylphenidate on Medicine Persistence Rates in Children with Attention-Deficit Hyperactivity Disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2017, 38, 603-610.	0.6	2
26	Attention-Deficit/Hyperactivity Disorder Medication Use in Adolescents: The Patient's Perspective. <i>Journal of Adolescent Health</i> , 2017, 61, 619-625.	1.2	22
27	A clinician's guide to ADHD treatment options. <i>Postgraduate Medicine</i> , 2017, 129, 657-666.	0.9	32
28	Determinants of Pharmacological Treatment Initiation and Persistence in Publicly Insured Adults With Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 546-554.	0.7	5
29	Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study. <i>Clinical Therapeutics</i> , 2017, 39, 2389-2398.	1.1	8
30	Beyond the pill: new medication delivery options for ADHD. <i>CNS Spectrums</i> , 2017, 22, 463-474.	0.7	6
31	Transcranial direct current stimulation improves clinical symptoms in adolescents with attention deficit hyperactivity disorder. <i>Journal of Neural Transmission</i> , 2017, 124, 133-144.	1.4	83
32	Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany. <i>European Journal of Health Economics</i> , 2017, 18, 893-904.	1.4	3
33	Lost in transition: A review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood. <i>Asia-Pacific Psychiatry</i> , 2017, 9, e12254.	1.2	21
34	Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1741-1751.	1.0	59
35	Trend, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit/hyperactivity disorder: a nationwide survey in Taiwan. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 643-651.	1.0	7
36	Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine. <i>Current Medical Research and Opinion</i> , 2018, 34, 619-632.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. <i>Family Practice</i> , 2018, 35, 142-150.	0.8	12
38	Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 279-288.	2.8	20
39	Perceptions of ADHD Among Diagnosed Children and Their Parents: A Systematic Review Using the Common-Sense Model of Illness Representations. <i>Clinical Child and Family Psychology Review</i> , 2018, 21, 57-93.	2.3	26
40	Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. <i>Research in Developmental Disabilities</i> , 2018, 72, 96-105.	1.2	44
41	Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 370-375.	0.7	13
42	Social adjustment and family function after drug switch from IR -methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2783-2791.	1.0	3
43	YouTube lens to attention deficit hyperactivity disorder: a social media analysis. <i>BMC Research Notes</i> , 2018, 11, 854.	0.6	17
44	Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 611-621.	1.0	3
45	Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD. <i>PLoS ONE</i> , 2018, 13, e0189749.	1.1	69
46	ADHD-Related Mental Health Issues of Young Adult Male Prisoners in PravieniÅ¡kÄ—s Correction House-Open Colony (Lithuania). <i>American Journal of Men's Health</i> , 2019, 13, 155798831987097.	0.7	2
47	A Maximum Dose for Methylphenidate—How Much Is Too Much?. <i>JAMA Pediatrics</i> , 2019, 173, 621.	3.3	0
48	From Toddlerhood to Adolescence: Which Characteristics Among Toddlers with Autism Spectrum Disorder Predict Adolescent Attention Deficit/Hyperactivity Symptom Severity? A Long-Term Follow-Up Study. <i>Journal of Autism and Developmental Disorders</i> , 2019, 49, 3191-3202.	1.7	10
49	Resumption of attention-deficit hyperactivity disorder medication in early adulthood: findings from a UK primary care prescribing study. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1589-1596.	2.8	4
50	Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1365-1373.	2.8	9
51	Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 2-8.	0.7	5
52	Negev Bedouin Teachers's Attitudes Toward ADHD and Its Pharmacological Treatment. <i>Qualitative Health Research</i> , 2019, 29, 418-430.	1.0	6
53	Mindfulness-based cognitive therapy <i>v</i>. treatment as usual in adults with ADHD: a multicentre, single-blind, randomised controlled trial. <i>Psychological Medicine</i> , 2019, 49, 55-65.	2.7	43
54	Examining Breaks and Resistance in Medication Adherence Among Adolescents With ADHD as Associated With School Outcomes. <i>Journal of Attention Disorders</i> , 2020, 24, 1148-1155.	1.5	10

#	ARTICLE	IF	CITATIONS
55	The Feasibility, Effectiveness, and Process of Change of Mindfulness-Based Cognitive Therapy for Adults With ADHD: A Mixed-Method Pilot Study. <i>Journal of Attention Disorders</i> , 2020, 24, 928-942.	1.5	14
56	The effectiveness of methylphenidate in improving cognition after brain injury in adults: a systematic review. <i>Brain Injury</i> , 2020, 34, 1-10.	0.6	7
57	Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: Results from a randomized clinical trial. <i>Addictive Behaviors</i> , 2020, 103, 106228.	1.7	12
58	Further evidence of low adherence to stimulant treatment in adult ADHD: an electronic medical record study examining timely renewal of a stimulant prescription. <i>Psychopharmacology</i> , 2020, 237, 2835-2843.	1.5	15
59	Parent and Teacher Training Increases Medication Adherence for Primary School Children With Attention-Deficit/Hyperactivity Disorder. <i>Frontiers in Pediatrics</i> , 2020, 8, 486353.	0.9	9
60	Medication Decision Making Among African American Caregivers of Children With ADHD: A Review of the Literature. <i>Journal of Attention Disorders</i> , 2021, 25, 1687-1698.	1.5	11
61	Treatment of ADHD in adults – prevalence of discontinuation and associated factors – results from a cross-sectional analysis of Danish register data. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 479-488.	0.7	4
62	Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. <i>BMC Psychiatry</i> , 2020, 20, 404.	1.1	162
63	YouTube for information about side effects of biologic therapy: A social media analysis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1645-1650.	0.9	15
64	Discrepancies in adolescent-mother dyads' reports of core depression symptoms: Association with adolescents' help-seeking in school and their somatic complaints. <i>Journal of Psychosomatic Research</i> , 2020, 137, 110222.	1.2	4
65	Contrasting effects of music on reading comprehension in preadolescents with and without ADHD. <i>Psychiatry Research</i> , 2020, 291, 113207.	1.7	12
66	Evidence for deprescription in primary care through an umbrella review. <i>BMC Family Practice</i> , 2020, 21, 100.	2.9	11
67	An innovative SMS intervention to improve adherence to stimulants in children with ADHD: Preliminary findings. <i>Journal of Psychopharmacology</i> , 2020, 34, 883-890.	2.0	11
68	Non-pharmacological interventions for adult ADHD: a systematic review. <i>Psychological Medicine</i> , 2020, 50, 529-541.	2.7	51
69	Exploring Factors Influencing Medication Adherence From Initiation to Discontinuation in Parents and Adolescents With Attention Deficit Hyperactivity Disorder. <i>Clinical Pediatrics</i> , 2020, 59, 285-296.	0.4	10
70	Affiliate Stigma and Related Factors in Family Caregivers of Children with Attention-Deficit/Hyperactivity Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 576.	1.2	31
71	Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. <i>Journal of Attention Disorders</i> , 2021, 25, 1417-1428.	1.5	15
72	Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 439-447.	0.7	9

#	ARTICLE	IF	CITATIONS
73	Patterns of long-term ADHD medication use in Australian children. Archives of Disease in Childhood, 2020, 105, 593-597.	1.0	14
74	Comorbidity and Factors Affecting Treatment Non-Persistence in ADHD. Journal of Attention Disorders, 2020, 24, 1276-1284.	1.5	3
75	Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. CNS Spectrums, 2021, 26, 202-221.	0.7	16
76	Using the Hub and Spoke Model of Telemental Health to Expand the Reach of Community Based Care in the United States. Community Mental Health Journal, 2021, 57, 49-56.	1.1	6
77	Editorial: Trials and Tribulations of Developing Adolescent Attention-Deficit/Hyperactivity Disorder Interventions: Digging Deep to Stay Motivated. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 685-687.	0.3	0
78	AD/HD & Learning Disorders. , 2021, , 237-255.		1
79	The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults. Journal of Clinical Psychopharmacology, 2021, 41, 100-102.	0.7	7
80	Vitamin D Deficiency in Patients with Attention Deficit Hyperactivity Disorder. Journal of Pharmaceutical Research International, 0, , 92-98.	1.0	0
81	Intentional Discontinuation of Psychostimulants Used to Treat ADHD in Youth: A Review and Analysis. Frontiers in Psychiatry, 2021, 12, 642798.	1.3	9
82	Methylphenidate Treatment Adherence and Persistence in Children in the Netherlands. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 205-213.	0.7	3
83	Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. JAMA Network Open, 2021, 4, e215335.	2.8	78
84	Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA. CNS Drugs, 2021, 35, 575-589.	2.7	4
85	Impact of the School Environment on Medical Treatment of Attention Deficit Hyperactivity Disorder: A Population-Wide Register Data Study of School-Wide Positive Behavioral Interventions and Supports. Child Development, 2021, 92, 2089-2105.	1.7	4
86	Influence of Substance Use Disorder on Treatment Retention of Adult-Attention-Deficit/Hyperactive Disorder Patients. A 5-Year Follow-Up Study. Journal of Clinical Medicine, 2021, 10, 1984.	1.0	2
87	Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder. International Journal of Clinical Practice, 2021, 75, e14330.	0.8	7
88	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD. Journal of Attention Disorders, 2022, 26, 857-869.	1.5	6
90	Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD. Drug Design, Development and Therapy, 2021, Volume 15, 2979-2985.	2.0	0
91	Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study. Current Medical Research and Opinion, 2021, 37, 2007-2014.	0.9	8

#	ARTICLE	IF	CITATIONS
92	Use of Medication to Treat Attention-Deficit/Hyperactivity Disorder in Young Children: The Role of Maternal History of Psychotropic Medication Use. <i>Child Psychiatry and Human Development</i> , 2021, , 1.	1.1	0
93	Diagnostic and Medication Treatment Disparities in African American Children with ADHD: a Literature Review. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 2027-2048.	1.8	8
94	Predictors of Changes in Height, Weight, and Body Mass Index After Initiation of Central Nervous System Stimulants in Children with Attention Deficit Hyperactivity Disorder. <i>Journal of Pediatrics</i> , 2022, 241, 115-125.e2.	0.9	8
95	Precision Medicine Care in ADHD: The Case for Neural Excitation and Inhibition. <i>Brain Sciences</i> , 2021, 11, 91.	1.1	30
96	Predictors at Toddlerhood for Long-Term Severity of ADHD Symptoms in Autism Spectrum Disorder. , 2021, , 3624-3630.		0
97	Adult Attention Deficit Hyperactivity Disorder (ADHD) in ASD. , 2019, , 175-194.		2
98	â€œDrugs Donâ€™t Work in Patients Who Donâ€™t Take Themâ€• <i>Zeitschrift FÃœr Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , 2019, 47, 528-534.	0.4	4
99	Collaborative medication-related roles for pediatric primary care psychologists.. <i>Clinical Practice in Pediatric Psychology</i> , 2018, 6, 61-72.	0.2	4
100	Supporting Japanese Mothers of Children with <scp>ADHD</scp>: Cultural Adaptation of the New Forest Parent Training Programme. <i>Japanese Psychological Research</i> , 2017, 59, 35-48.	0.4	12
101	â€œMy ADHD Hellbrainâ€• A Twitter Data Science Perspective on a Behavioural Disorder. <i>Journal of Data and Information Science</i> , 2021, 6, 13-34.	0.5	10
102	Specific genes associated with adverse events of methylphenidate use in the pediatric population: A systematic literature review. <i>Journal of Research in Pharmacy Practice</i> , 2017, 6, 65.	0.2	13
103	Factors that Affect the Adherence to ADHD Medications during a Treatment Continuation Period in Children and Adolescents: A Nationwide Retrospective Cohort Study Using Korean Health Insurance Data from 2007 to 2011. <i>Psychiatry Investigation</i> , 2017, 14, 158.	0.7	21
104	Self-Reported Effects of Cannabis on ADHD Symptoms, ADHD Medication Side Effects, and ADHD-Related Executive Dysfunction. <i>Journal of Attention Disorders</i> , 2022, 26, 942-955.	1.5	14
105	Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. <i>JAMA Network Open</i> , 2021, 4, e2130795.	2.8	17
106	Using discrete choice experiment to investigate patientsâ€™ and parentsâ€™ preferences for initiating ADHD medication. <i>Journal of Mental Health</i> , 2023, 32, 373-385.	1.0	1
108	Managing Adult Attention-Deficit/Hyperactivity Disorder: To Treat or Not To Treat?. <i>Psychiatric Annals</i> , 2017, 47, 315-321.	0.1	0
109	Patterns and Persistence of Pharmacotherapy for Children and Adolescents with Attention Deficit Hyperactivity Disorder in South Korea. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 216-223.	0.0	1
110	Clinical and Neuropsychological Factors Associated with Treatment Response and Adverse Events of Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder. <i>SoaÅ¡\$ceongso'nyeon Jeongsin Yihag</i> , 2019, 30, 74-82.	0.3	1

#	ARTICLE	IF	CITATIONS
111	Adult ADHD in Other Neurodevelopmental Disorders. , 2020, , 97-118.		0
112	Predictors at Toddlerhood for Long Term Severity of ADHD Symptoms in Autism Spectrum Disorder. , 2020, , 1-7.		0
115	The Relationship between Serum Vitamin D Level and Attention Deficit Hyperactivity Disorder. Iranian Journal of Child Neurology, 2015, 9, 48-53.	0.2	24
116	Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective. Journal of Medical Economics, 2022, 25, 193-205.	1.0	12
117	Why young people stop taking their attention deficit hyperactivity disorder medication: A thematic analysis of interviews with young people. Child: Care, Health and Development, 2022, 48, 724-735.	0.8	9
118	Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 168-179.	0.5	4
119	Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association, 2022, 11, e024119.	1.6	10
120	Eliciting preferences for continuing medication among adult patients and parents of children with attention-deficit hyperactivity disorder. Health Expectations, 2022, , .	1.1	1
121	Review of barriers and interventions to promote treatment engagement for pediatric attention deficit hyperactivity disorder care. World Journal of Psychiatry, 2021, 11, 1206-1227.	1.3	14
123	Association Between Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder and Long-term Unemployment Among Working-Age Individuals in Sweden. JAMA Network Open, 2022, 5, e226815.	2.8	5
124	Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. BMC Psychiatry, 2022, 22, .	1.1	2
125	Transition from child and adolescent mental health care to adult services for young people with Attention-Deficit/Hyperactivity Disorder (ADHD) or Autism Spectrum Disorder (ASD) in Europe: Barriers and recommendations. L'Encephale, 2022, 48, 555-559.	0.3	4
126	Generalized structural equation modeling: Symptom heterogeneity in attention-deficit/hyperactivity disorder leading to poor treatment efficacy. World Journal of Psychiatry, 2022, 12, 787-800.	1.3	0
127	Effectiveness of Clinic-Based Brief Behavioral Intervention (BBI) in Long-term Reduction of ADHD Symptoms Among Preschoolers. Journal of Clinical Psychology in Medical Settings, 2023, 30, 403-414.	0.8	1
128	Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States – a retrospective claims analysis. BMC Psychiatry, 2022, 22, .	1.1	4
129	Attention-Deficit Hyperactivity Disorder. , 2022, , 1-37.		0
130	Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by CYP2D6 genetic variations. Drug Metabolism and Personalized Therapy, 2022, .	0.3	2
131	Attention-Deficit Hyperactivity Disorder. , 2022, , 4459-4495.		0

#	ARTICLE	IF	CITATIONS
132	Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study. <i>Advances in Therapy</i> , 2022, 39, 5487-5503.	1.3	0
133	ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA): a multi-centre prospective cohort study protocol. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	6
134	An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder. <i>Discover Mental Health</i> , 2023, 3, .	1.0	8
135	Pharmacological Treatment of Children and Adolescents Diagnosed with Attention-deficit/hyperactivity Disorder at Mental Health Services in Qatar: A Retrospective Study. <i>Emirates Medical Journal</i> , 2022, 04, .	0.3	0
137	Associations of meeting 24-h movement behavior guidelines with cognitive difficulty and social relationships in children and adolescents with attention deficit/hyperactive disorder. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2023, 17, .	1.2	14
138	Exploring the Relationship between Cardiorespiratory Fitness and Executive Functioning in Adults with ADHD. <i>Brain Sciences</i> , 2023, 13, 673.	1.1	1
139	Therapeutic Use of Dopamine Enhancers (Stimulants). , 2023, , 1-41.		0